Impact of Alternative Diagnostic Labels for Melanoma In Situ
Introduction
Melanoma in situ has a low risk for life and health. However, current names make it hard for patients to understand the risks compared to more serious melanomas. This study will test if using different names affects patient decisions and anxiety.
Study Methods
This study is an online experiment with participants randomly assigned to one of three labels:
- Control: Melanoma in situ
- Intervention 1: Low-risk melanocytic neoplasm
- Intervention 2: Low-risk melanocytic neoplasm, in situ
We need 1,668 participants. The main goals are to see:
- If patients choose further surgery or no surgery.
- If patients prefer follow-ups on their own or scheduled ones with a doctor.
We will also measure anxiety about diagnosis, perceived risks, and decisions about surgery and follow-ups.
Ethics and Results
This study is registered and approved by ethics boards. Results will be published in a medical journal, and a simple summary will be available on the Wiser Healthcare website.
Trial Registration Number
Australian New Zealand Clinical Trials Registry (ID 386943).
Clinical Trials and Everyday Practice
Clinical trials are essential for developing safe treatments. To help incorporate research into daily medical care, we offer DocSym, an AI-driven platform that combines ICD-11 standards, clinical protocols, and research in one easy-to-use resource for healthcare providers.
Enhancing Healthcare with Technology
In today’s healthcare landscape, efficiency is key. Our mobile apps improve scheduling, treatment monitoring, and telemedicine, making patient management easier and expanding digital services.
Improve Outcomes with AI
By using AI, clinics can streamline workflows, enhance patient outcomes, and reduce paperwork. Discover how we can assist at aidevmd.com.
